{
  "meta": {
    "title": "11_Blood_Bank_Transfusion_Medicine",
    "url": "https://brainandscalpel.vercel.app/11-blood-bank-transfusion-medicine-90cc6c46.html",
    "scrapedAt": "2025-11-30T06:57:00.343Z"
  },
  "questions": [
    {
      "id": 98926,
      "choices": [
        {
          "id": 299926,
          "text": "Fibrinogen,"
        },
        {
          "id": 299927,
          "text": "Factor VIII"
        },
        {
          "id": 299928,
          "text": "Von Willebrand Factor"
        },
        {
          "id": 299929,
          "text": "All the above"
        }
      ],
      "text": "Cryoprecipitate contains",
      "unique_key": "Q1171562",
      "question_audio": null,
      "question_video": null,
      "map_id": 34907369,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Correct Response Explanation: Cryoprecipitate is a blood product derived from plasma and contains a concentrated mix of clotting factors and proteins that are essential for coagulation. It is used in clinical situations such as hypofibrinogenemia, massive bleeding, or certain bleeding disorders. The components include: Fibrinogen: Essential for blood clot formation. Cryoprecipitate is often used to replace fibrinogen in conditions like disseminated intravascular coagulation (DIC). Factor VIII: A critical clotting factor for the intrinsic pathway, used in managing hemophilia A or severe bleeding. Von Willebrand Factor (vWF): Important for platelet adhesion and aggregation. Cryoprecipitate is sometimes used to treat bleeding episodes in von Willebrand disease (vWD), especially if specific factor concentrates are unavailable. Thus, cryoprecipitate contains all of the above components, making (D) the correct answer. Incorrect Response Explanations: (A) Fibrinogen: While fibrinogen is present in cryoprecipitate, it is not the sole component. Therefore, this option is incomplete. (B) Factor VIII: Factor VIII is included in cryoprecipitate but is not the only clotting factor it contains. Thus, this option is incomplete. (C) Von Willebrand Factor: Cryoprecipitate does contain von Willebrand factor, but it also includes fibrinogen and Factor VIII, making this option incomplete as well.",
      "correct_choice_id": 299929,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78843371705130470/78843371705130470.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78843371705130470/78843371705130470.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98927,
      "choices": [
        {
          "id": 299930,
          "text": "Kell"
        },
        {
          "id": 299931,
          "text": "Duffy"
        },
        {
          "id": 299932,
          "text": "MNS"
        },
        {
          "id": 299933,
          "text": "Kidd"
        }
      ],
      "text": "After ABO and Rh, the next most immunogenic blood group system is .......",
      "unique_key": "Q2724648",
      "question_audio": null,
      "question_video": null,
      "map_id": 34101071,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Kell. After ABO and Rh, the Kell blood group system is the most immunogenic. The Kell system includes several antigens, of which the K (Kell) antigen is the most clinically significant. Anti-K antibodies are highly immunogenic and can lead to severe hemolytic transfusion reactions and hemolytic disease of the newborn (HDN). The Kell system is second only to ABO and Rh in terms of the likelihood of antibody formation following transfusion or pregnancy. This is due to the high antigenicity of the K antigen, which stimulates a strong immune response in sensitized individuals. B. Duffy This option is incorrect because the Duffy blood group system (e.g., Fy^a and Fy^b antigens) is less immunogenic compared to the Kell system. While Duffy antibodies can cause transfusion reactions and mild hemolytic disease of the newborn, they are not as potent or common as anti-Kell antibodies. Additionally, Duffy antigens are clinically significant in the context of malaria, as they serve as receptors for Plasmodium vivax invasion, but they are not as immunogenic in transfusion medicine. C. MNS This option is incorrect because the MNS blood group system, while polymorphic and clinically significant in certain cases, is less immunogenic compared to Kell. Antibodies to MNS antigens, such as anti-M or anti-S, are typically weaker and rarely cause severe hemolytic transfusion reactions or HDN. D. Kidd This option is incorrect because although the Kidd blood group system (e.g., Jk^a and Jk^b antigens) can cause delayed hemolytic transfusion reactions, its antigens are less immunogenic than Kell antigens. Kidd antibodies are known for their ability to disappear from circulation, making detection challenging, but their immunogenic potential is still lower compared to the Kell system.",
      "correct_choice_id": 299930,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48074111705131401/48074111705131401.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48074111705131401/48074111705131401.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98928,
      "choices": [
        {
          "id": 299934,
          "text": "Allergic reactions"
        },
        {
          "id": 299935,
          "text": "Anaphylactic reactions"
        },
        {
          "id": 299936,
          "text": "Febrile non haemolytic transfusion reactions"
        },
        {
          "id": 299937,
          "text": "Graft versus host disease"
        }
      ],
      "text": "Most frequent reaction associated with the transfusion of cellular blood components is ?",
      "unique_key": "Q5381517",
      "question_audio": null,
      "question_video": null,
      "map_id": 34193638,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Febrile non-hemolytic transfusion reactions (FNHTRs). FNHTRs are the most common adverse reactions associated with the transfusion of cellular blood components, such as red blood cells or platelets. They occur due to the immune response to donor white blood cells (WBCs) or their cytokines, which accumulate during blood storage. FNHTRs typically present as fever, chills, and mild discomfort during or shortly after transfusion but are generally not life-threatening. These reactions are more common with transfusions of older blood products, as cytokine levels increase over time. Prestorage leukoreduction (removal of WBCs) has significantly reduced the incidence of FNHTRs. A. Allergic reactions This option is incorrect because allergic reactions, although relatively common, occur less frequently than FNHTRs. They are caused by recipient hypersensitivity to plasma proteins in the donor blood. Symptoms include urticaria, itching, and mild rash, which are usually mild and manageable with antihistamines. Severe allergic reactions are rare. B. Anaphylactic reactions This option is incorrect because anaphylactic reactions are rare and occur in individuals with a complete deficiency of immunoglobulin A (IgA) who have anti-IgA antibodies. These reactions are severe and can present as hypotension, bronchospasm, and respiratory distress. However, their incidence is far lower than FNHTRs. D. Graft versus host disease (GVHD) This option is incorrect because transfusion-associated GVHD is extremely rare. It occurs when viable donor lymphocytes in the transfused blood attack the recipient's tissues. This is more common in immunocompromised individuals or in cases of transfusion from a relative with similar HLA types. GVHD can be prevented by irradiating blood components before transfusion.",
      "correct_choice_id": 299936,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9068801705131426/9068801705131426.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9068801705131426/9068801705131426.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98929,
      "choices": [
        {
          "id": 299938,
          "text": "2-4"
        },
        {
          "id": 299939,
          "text": "5-7"
        },
        {
          "id": 299940,
          "text": "10-12"
        },
        {
          "id": 299941,
          "text": "15-18"
        }
      ],
      "text": "Platelets are stored in plasma or in additive solution up to ....... days at 20–24°C ?",
      "unique_key": "Q1181004",
      "question_audio": null,
      "question_video": null,
      "map_id": 34968558,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) 5–7 days. Platelets are stored at 20–24°C in plasma or in an additive solution with constant gentle agitation to maintain their viability and function. Under these conditions, platelets can be stored for up to 7 days, depending on the regulatory guidelines and the type of storage system used. However, in most settings, the storage limit is 5 days due to concerns about bacterial contamination, which is a significant risk at room temperature. Platelets stored beyond this duration may lose their functionality and pose safety risks to recipients. To ensure safety, testing for bacterial contamination is often performed before transfusion. A. 2–4 This option is incorrect because platelets are specifically designed to maintain functionality beyond 2–4 days under proper storage conditions. While shorter storage durations may minimize risks such as bacterial contamination, the practical storage limit of platelets is typically 5–7 days. C. 10–12 This option is incorrect because platelets cannot be stored for such extended durations at 20–24°C. Prolonged storage at room temperature leads to reduced platelet viability and an increased risk of bacterial growth, making this option unsafe and impractical. D. 15–18 This option is incorrect because storage for 15–18 days is far beyond the acceptable limit for platelets. Extended storage would render the platelets nonfunctional and greatly increase the risk of bacterial contamination, making them unsuitable for transfusion.",
      "correct_choice_id": 299939,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62439451705131438/62439451705131438.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62439451705131438/62439451705131438.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98930,
      "choices": [
        {
          "id": 299942,
          "text": "Fibrinogen"
        },
        {
          "id": 299943,
          "text": "Antithrombin"
        },
        {
          "id": 299944,
          "text": "Albumin"
        },
        {
          "id": 299945,
          "text": "All the above"
        }
      ],
      "text": "FFP contains?",
      "unique_key": "Q5941982",
      "question_audio": null,
      "question_video": null,
      "map_id": 34026314,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Fresh Frozen Plasma (FFP) is a blood product derived from the plasma portion of whole blood that is frozen within hours of collection to preserve its components. FFP contains multiple essential proteins and coagulation factors, making it a versatile therapeutic product for managing bleeding disorders. Fibrinogen: FFP is a rich source of fibrinogen, an essential protein involved in clot formation. It plays a crucial role in maintaining hemostasis, and FFP is often used to replenish fibrinogen levels in patients with conditions such as disseminated intravascular coagulation (DIC) or massive hemorrhage. Antithrombin: FFP also contains antithrombin, a natural anticoagulant that helps regulate the coagulation cascade by inhibiting thrombin and factor Xa. This makes FFP useful in conditions where antithrombin levels are low, such as congenital antithrombin deficiency or during certain anticoagulant therapies. Albumin: Albumin is a plasma protein present in FFP, though in lower concentrations compared to dedicated albumin preparations. Albumin helps maintain oncotic pressure and plays a role in fluid balance. A. Fibrinogen This option is correct because fibrinogen is one of the key coagulation factors present in FFP. It is critical for clot formation and hemostasis, and FFP is often administered to restore fibrinogen levels in bleeding patients. B. Antithrombin This option is correct because FFP contains antithrombin, which regulates the coagulation cascade. Its presence makes FFP an effective treatment for clotting disorders where natural anticoagulant levels are insufficient. C. Albumin This option is correct because albumin is naturally found in plasma, including FFP, though it is not the primary therapeutic reason for administering FFP. It contributes to maintaining oncotic pressure and fluid balance in the body.",
      "correct_choice_id": 299945,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11968181705131454/11968181705131454.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11968181705131454/11968181705131454.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98931,
      "choices": [
        {
          "id": 299946,
          "text": "10"
        },
        {
          "id": 299947,
          "text": "25"
        },
        {
          "id": 299948,
          "text": "50"
        },
        {
          "id": 299949,
          "text": "80"
        }
      ],
      "text": "Cryoprecipitate contains....... units of factor VIII",
      "unique_key": "Q2248103",
      "question_audio": null,
      "question_video": null,
      "map_id": 34382840,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) 80. Cryoprecipitate is a blood product derived from fresh frozen plasma (FFP) that is rich in specific clotting factors. It contains approximately 80 units of factor VIII per bag, along with other important coagulation proteins such as fibrinogen, von Willebrand factor (vWF), and factor XIII. Cryoprecipitate is commonly used to treat conditions such as hemophilia A (factor VIII deficiency), hypofibrinogenemia, and von Willebrand disease when other treatments are unavailable or impractical. The standardized level of at least 80 units of factor VIII ensures its effectiveness in managing bleeding disorders. A. 10 This option is incorrect because 10 units of factor VIII is far below the concentration typically found in cryoprecipitate. Such a low amount would be insufficient for therapeutic purposes, particularly in managing significant bleeding or factor VIII deficiencies. B. 25 This option is incorrect because 25 units of factor VIII, although higher than 10, is still significantly less than the actual concentration in cryoprecipitate. It does not meet the standardized content required for effective clinical use. C. 50 This option is incorrect because while 50 units of factor VIII is closer to the actual value, it still underestimates the minimum amount found in cryoprecipitate. The clinical standard ensures that each unit contains at least 80 units of factor VIII for optimal therapeutic effect.",
      "correct_choice_id": 299949,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20463971705131466/20463971705131466.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20463971705131466/20463971705131466.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98932,
      "choices": [
        {
          "id": 299950,
          "text": "1-2"
        },
        {
          "id": 299951,
          "text": "3-5"
        },
        {
          "id": 299952,
          "text": "7-10"
        },
        {
          "id": 299953,
          "text": "15-20"
        }
      ],
      "text": "Post-transfusion purpura occurs …….. days after platelet transfusion ?",
      "unique_key": "Q6630413",
      "question_audio": null,
      "question_video": null,
      "map_id": 34234724,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) 7–10 days. Post-transfusion purpura (PTP) is a rare but serious condition characterized by a rapid drop in platelet count (thrombocytopenia) occurring 7–10 days after a platelet transfusion. PTP is caused by the development of alloantibodies, typically directed against platelet antigens such as HPA-1a. In individuals who are negative for the implicated antigen, the immune system destroys both transfused and native platelets, leading to severe thrombocytopenia and purpura. The condition often resolves spontaneously within a few weeks, but intravenous immunoglobulin (IVIG) is commonly used to accelerate recovery. A. 1–2 This option is incorrect because post-transfusion purpura does not occur immediately after transfusion. A 1–2-day onset is more consistent with other transfusion reactions, such as febrile non-hemolytic reactions or allergic reactions, rather than PTP. B. 3–5 This option is incorrect because while some immune-mediated transfusion reactions can manifest within this timeframe, PTP typically has a delayed onset of 7–10 days due to the time required for alloantibody production and platelet destruction. D. 15–20 This option is incorrect because 15–20 days is far beyond the usual time frame for PTP onset. By this time, any alloimmune response would likely have resolved or presented earlier within the typical 7–10-day window.",
      "correct_choice_id": 299952,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25840681705131479/25840681705131479.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25840681705131479/25840681705131479.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98933,
      "choices": [
        {
          "id": 299954,
          "text": "Hyperkalemia"
        },
        {
          "id": 299955,
          "text": "Hypokalemia"
        },
        {
          "id": 299956,
          "text": "Hypocalcemia"
        },
        {
          "id": 299957,
          "text": "Both a and c"
        }
      ],
      "text": "Which of the following electrolyte abnormality is related to blood transfusion ?",
      "unique_key": "Q5152021",
      "question_audio": null,
      "question_video": null,
      "map_id": 34791491,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Both a and c. Blood transfusions can lead to two common electrolyte abnormalities: Hyperkalemia (A): Blood stored in bags, particularly red blood cells, can release potassium over time due to cell lysis. This results in an increase in serum potassium levels, which can be clinically significant, particularly when large volumes of blood are transfused. The potassium levels rise especially in stored blood that has been kept for longer periods. Hypocalcemia (C): The anticoagulant used in blood bags (usually citrate) binds calcium in the recipient's blood, leading to a transient decrease in serum calcium levels. If large volumes of blood are transfused rapidly, citrate infusion can exceed the liver's ability to metabolize it, causing hypocalcemia. This may lead to symptoms like tetany or arrhythmias. A. Hyperkalemia This option is correct, as hyperkalemia is a known complication of blood transfusion, especially when stored blood is administered. The potassium released from transfused red blood cells can cause elevated potassium levels in the recipient, which can lead to serious cardiac arrhythmias if not monitored carefully. B. Hypokalemia This option is incorrect because hypokalemia is not commonly associated with blood transfusion. On the contrary, hyperkalemia due to potassium release from stored red blood cells is more likely. C. Hypocalcemia This option is correct, as hypocalcemia can occur during blood transfusion due to the binding of calcium by citrate in stored blood. This is particularly a concern with rapid or massive transfusions.",
      "correct_choice_id": 299957,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11558921705131500/11558921705131500.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11558921705131500/11558921705131500.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98934,
      "choices": [
        {
          "id": 299958,
          "text": "Smoking"
        },
        {
          "id": 299959,
          "text": "Chronic alcoholism"
        },
        {
          "id": 299960,
          "text": "Liver surgery"
        },
        {
          "id": 299961,
          "text": "All"
        }
      ],
      "text": "Which of the following increases the risk of developing Transfusion related Acute Lung Injury ?",
      "unique_key": "Q3391151",
      "question_audio": null,
      "question_video": null,
      "map_id": 34964209,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All. Transfusion-Related Acute Lung Injury (TRALI) is a serious and potentially life-threatening condition that occurs within 6 hours of blood transfusion, characterized by acute respiratory distress and non-cardiogenic pulmonary edema. Several factors increase the risk of developing TRALI, including: Smoking (A): Smoking damages the lungs and impairs the immune response, making the respiratory system more vulnerable to injury. This increases the risk of developing TRALI in patients who receive blood transfusions. Chronic alcoholism (B): Chronic alcohol use can alter the immune system, decrease lung function, and lead to liver damage, which in turn increases the susceptibility to TRALI. Alcohol-induced liver dysfunction can also affect the clearance of inflammatory mediators, contributing to TRALI. Liver surgery (C): Liver surgery can lead to compromised liver function, which plays a role in managing inflammatory mediators and detoxifying the body. Inflammatory responses may be more pronounced after liver surgery, making the lungs more susceptible to damage from transfused blood components. A. Smoking This option is correct because smoking impairs pulmonary function and promotes chronic inflammation, both of which increase the risk of TRALI following a transfusion. Smokers may have a compromised immune response, which can exacerbate inflammatory reactions in the lungs when exposed to transfused blood products. B. Chronic alcoholism This option is correct because chronic alcohol consumption can weaken the immune system and cause liver damage, both of which are associated with an increased risk of TRALI. Alcohol-related damage to lung and liver tissues further enhances the body's susceptibility to TRALI after a transfusion. C. Liver surgery This option is correct because liver surgery affects liver function and the body's ability to manage systemic inflammation. The inflammation that follows liver surgery can increase the likelihood of developing TRALI, particularly when a transfusion is involved.",
      "correct_choice_id": 299961,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42521341705131516/42521341705131516.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42521341705131516/42521341705131516.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 98935,
      "choices": [
        {
          "id": 299962,
          "text": "Renal cancers"
        },
        {
          "id": 299963,
          "text": "Hepatocellular carcinoma"
        },
        {
          "id": 299964,
          "text": "Cerebellar hemangioblastomas"
        },
        {
          "id": 299965,
          "text": "All the above"
        }
      ],
      "text": "Erythrocytosis can occur as paraneoplastic syndrome in :",
      "unique_key": "Q9919565",
      "question_audio": null,
      "question_video": null,
      "map_id": 34408940,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Erythrocytosis, also known as polycythemia, can occur as a paraneoplastic syndrome in various cancers. It is caused by the secretion of erythropoietin (EPO) or EPO-like substances by tumors, which stimulate red blood cell production. This condition is typically seen in the following cancers: Renal cancers (A): Renal cell carcinoma is one of the most common malignancies associated with paraneoplastic erythrocytosis. Tumors of the kidneys can produce erythropoietin, which leads to increased red blood cell production, resulting in erythrocytosis. Hepatocellular carcinoma (B): Hepatocellular carcinoma (HCC) can also produce erythropoietin or other erythropoiesis-stimulating factors, leading to erythrocytosis. This is seen as a paraneoplastic effect in a significant proportion of patients with advanced liver cancer. Cerebellar hemangioblastomas (C): These tumors, particularly those associated with von Hippel-Lindau syndrome, can also secrete erythropoietin, causing erythrocytosis. This is less common but is still a recognized paraneoplastic phenomenon. A. Renal cancers This option is correct because renal cancers, especially renal cell carcinoma, are commonly associated with paraneoplastic erythrocytosis. These tumors can produce excess erythropoietin, which drives the production of red blood cells. B. Hepatocellular carcinoma This option is correct because hepatocellular carcinoma can lead to erythrocytosis by producing erythropoietin or erythropoiesis-stimulating factors, which increase red blood cell production in the bone marrow. C. Cerebellar hemangioblastomas This option is correct because cerebellar hemangioblastomas, particularly in the context of von Hippel-Lindau syndrome, are also associated with paraneoplastic erythrocytosis due to their ability to secrete erythropoietin.",
      "correct_choice_id": 299965,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/46490401705131529/46490401705131529.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/46490401705131529/46490401705131529.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}